Insight, China's Pharmaceutical Industry

Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with...

Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026

Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) announced a strategic partnership with BeOne...

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from...

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026

TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced...

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a...

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Fineline Cube May 27, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received separate clinical...

Company

Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion

Fineline Cube May 27, 2026

Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive...

Company

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

Fineline Cube May 27, 2026

The Global Medical Device Training, Exhibition, Trading and Innovation Center was officially inaugurated this week...

Company Drug

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...

Company Drug

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and its U.S. partner Kailera Therapeutics...

Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026

Insilico Medicine (HKG: 3696) and Human Life Foundation Models (HLFM), a newly established spin-off from...

Company Drug

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in China...

Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026

Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics...

Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026

Shanghai Simpletouch Robot Co., Ltd. has filed its prospectus with the Hong Kong Stock Exchange...

Company Deals

Qingfeng Pharmaceutical Secures Greater China Rights to Merz’s Inbrija Levodopa Inhalation Powder for Parkinson’s Disease OFF Episodes

Fineline Cube May 26, 2026

Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German...

Company Deals

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Fineline Cube May 26, 2026

Peak Pharmaceutical Co., Ltd. announced a strategic partnership with SPH Kyuan Trade, a core subsidiary...

Others

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

Fineline Cube May 26, 2026

Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has...

Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026

China’s National Medical Products Administration (NMPA) has released the “Compliance Guidelines for Online Retail of...

Company Drug

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

Fineline Cube May 26, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical...

Insight, China's Pharmaceutical Industry

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635

Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Qingfeng Pharmaceutical Secures Greater China Rights to Merz’s Inbrija Levodopa Inhalation Powder for Parkinson’s Disease OFF Episodes

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories